As the conversion from HER2-zero to HER2-positive between pre-NAT primary breast cancers and post-NAT residual lesions is uncommon, and little has been learned about the clinical implications of the change in HER2 status after NAT, the present standard of treatment is determined by the receptor expression of the patient’s primary breast cancer (45). This evidence concerns the gene ERBB2 and breast carcinoma.